Safe, Innovative and Accessible Medicines in Europe: A Renewed Strategy for Patients and the Pharmaceutical Sector

In: European Journal of Health Law
Annagrazia Altavilla Espace Éthique Méditerranéen/Paca Corse, Assistance Publique Hôpitaux de Marseille Marseille France Teddy Network, Gianni Benzi Pharmacological Research Foundation Italy

Search for other papers by Annagrazia Altavilla in
Current site
Google Scholar
View More View Less
Download Citation Get Permissions

Access options

Get access to the full article by using one of the access options below.

Institutional Login

Log in with Open Athens, Shibboleth, or your institutional credentials

Login via Institution


Buy instant access (PDF download and unlimited online access):



European Union (eu) action in the pharmaceutical sector has always had the dual objective of safeguarding public health by providing Europe with safe and effective medicines, while stimulating research, boosting innovation, and supporting the competitiveness of industry. To face major health, economic and scientific challenges, a series of measures have been adopted. Specific legal frameworks have been set up to improve patient safety by reducing the infiltration of counterfeit medicines into the supply chain, to increase the safety of medicines by modernising the pharmacovigilance system, as well as improving patient access by requiring high-quality health and medicine information. This article provides an overview of the new eu strategy aimed at increasing the safety and involvement of European patients, as well as the competitiveness of pharmaceutical industry in accordance with the principle of transparency. The analysis is carried out from a patients’ perspective addressing some paediatric specifications.

Content Metrics

All Time Past Year Past 30 Days
Abstract Views 439 84 6
Full Text Views 210 1 0
PDF Views & Downloads 66 4 0